CDIO vs TMDX vs NTRA vs RXRX

For growth investors, Cardio Diagnostics Holdings, Inc.

(CDIO) is the stronger pick with 104. 5% revenue growth year-over-year, versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). TransMedics Group, Inc. (TMDX) offers the better valuation at 15. 0x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Cardio Diagnostics Holdings, Inc. (CDIO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, TransMedics Group, Inc.

(TMDX) delivered a total return of +200. 7%, compared to -99. 4% for Cardio Diagnostics Holdings, Inc. (CDIO). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus CDIO's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 26β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 153% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Recursion Pharmaceuticals, Inc. (RXRX) carries a lower debt/equity ratio of 7% versus 99% for TransMedics Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cardio Diagnostics Holdings, Inc.

(CDIO) is pulling ahead at 104. 5% versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). On earnings-per-share growth, the picture is similar: TransMedics Group, Inc. grew EPS 382. 2% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, CDIO leads at 238. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TransMedics Group, Inc.

(TMDX) is the more profitable company, earning 31. 4% net margin versus -240. 3% for Cardio Diagnostics Holdings, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMDX leads at 17. 9% versus -239. 8% for CDIO. At the gross margin level — before operating expenses — CDIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RXRX: 236.

4% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 3. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +20. 9%, CDIO: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.